Atea Pharmaceuticals, Inc. (AVIR) Form 8-K — Aug 12, 2026
Atea Pharmaceuticals reported a second-quarter 2026 net loss of $32.9 million, or $0.41 per share, improved from a $37.2 million loss, or $0.44 per share, in the year-ago quarter, as R&D expense fell to $28.2 million and G&A expense to $7.0 million. Cash and investments stood at $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025, with working capital of $200.5 million funding the path toward regulatory filing.
Key figures
- Total Assets
- 232282000
- Cash Position
- 219465000
- Working capital
- 200541000
- Cash dec 31 2025
- 301830000
- Total liabilities
- 28124000
- Ga expense q2 2025
- 9070000
- Ga expense q2 2026
- 6949000
- Cbeyond svr bem rzr
- 93.9%
- Cbeyond svr sof vel
- 94.8%
- Cforward enrollment
- more than 880 patients across 17 countries; enrollment completed June 2026
- Rnd expense q2 2025
- 32275000
- Rnd expense q2 2026
- 28150000
- Stockholders equity
- 204158000
- Cbeyond mitt patients
- 905
- Nda submission target
- Q2 2027
- Non inferiority margin
- 5%
- Cforward topline timing
- early Q1 2027
- Cbeyond cirrhotic patients
- 184
- Cbeyond non cirrhotic patients
- 721
- Us new hcv infections annually
- approximately 160,000
- Cbeyond cirrhotic svr both arms
- 95.4%
- Us hcv annual market opportunity
- $2.5 billion net sales
- Us hcv patients treated annually
- approximately 85,000
- Weighted avg shares basic diluted
- 80050518
- Cbeyond non cirrhotic svr bem rzr 8wk
- 93.5%
- Cbeyond non cirrhotic svr sof vel 12wk
- 94.6%
Price after filing
1 day: +0.2%7 days: +10.5%30 days: +4.9%
Close on the filing date to close N calendar days later (from $5.06). Historical, not a forecast.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.